Trials / Unknown
UnknownNCT03062397
Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Jeil Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JPI-289 Low-dose | JPI-289 Low dose will be intravenously administered during 24 hours |
| DRUG | JPI-289 High-dose | JPI-289 High dose will be intravenously administered during 24 hours |
| DRUG | Placebo | Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours |
Timeline
- Start date
- 2016-12-09
- Primary completion
- 2020-12-01
- Completion
- 2021-12-01
- First posted
- 2017-02-23
- Last updated
- 2019-11-18
Locations
15 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03062397. Inclusion in this directory is not an endorsement.